Biotechnology is indisputably one of the fastest-growing and most promising industries. Virtually immune to swings in the economic cycles, biotech stocks continue to perform steadily as high-tech stocks lose their steam. In Biotech Investing, Jim McCamant offers proven strategies and savvy advice on how to capitalize on the unprecedented opportunities in this high-potential sector. Written by a recognized authority, this book dissects biotech business models from start-up to IPO and discusses in detail the most important factors that affect biotech research. Comprehensive in scope, it looks at the best and worst biotech contenders, discusses all the most newsworthy developments in the field, and shows how they translate into business success or failure. It outlines simple criteria for choosing the best biotech stocks and for understanding the sometimes complicated dynamics of this sector.
Jim McCamant is editor of the Medical Technology Stock Letter, the oldest biotech newsletter in the country. A nationally recognized authority in biotech investing, he is a constant news source for major media publications, including BusinessWeek, the Wall Street Journal, and Worth Magazine. He lives in Berkeley, California.
Jim McCamant is editor of the Medical Technology Stock Letter, the oldest biotech newsletter in the country. A nationally recognized authority in biotech investing, he is a constant news source for major media publications, including BusinessWeek, the Wall Street Journal, and Worth Magazine. He lives in Berkeley, California.
